/ /

Advances

Advanced ovarian cancer drug approvedFDA recently approved rucaparib (Rubraca, Clovis Oncology) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies.
FDA green lights first treatment for rare spinal diseaseFDA approved nusinersen (Spinraza, Biogen), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Study: Compound found in vegetables could have anti-aging effectsA recent study found that the compound, NMN, boosts production of NAD+ in mice and could have anti-aging effects along with additional benefits, but more research is necessary to determine its effect on humans.
New diabetes combo drug available soonA new combination drug for type 2 diabetes will available in the US in the coming months.
FDA approves expansion of Avastin in ovarian cancerFDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.
New drug indication could net more than $1 billionFDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion.
FDA approves 2 injectable diabetes drugsTwo new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.
Ixazomib for multiple myelomaFDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infectionFDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis.
Research looks at melanocyte role in tumor formationWhile melanocytes have strong mechanisms for repair, those in individuals with certain risk factors may carry impaired repair responses. Studies have begun to examine melanocytes in patients at risk for developing melanoma with the hope of developing strategies for preventing deadly tumors.

Poll

View Results